Abiraterone

Contraindicated

Abiraterone Ensitrelvir Increased CYP3A substrates exposure and an increased risk of CYP3A substrates-related adverse effects Details

Major

Abiraterone Abametapir Increased exposure of CYP3A4 substrate Details Abiraterone Acarbose Prandase® An increased risk of severe hypoglycemia Details Abiraterone Albiglutide An increased risk of severe hypoglycemia Details Abiraterone Alogliptin Nesina An increased risk of severe hypoglycemia Details Abiraterone Amiodarone Nexterone Increased amiodarone exposure and an increased risk of amiodarone-related adverse effects Details Abiraterone Amphetamine Dexedrine Increased amphetamine exposure and increased risk of serotonin syndrome Details Abiraterone Apalutamide Erleada Reduced abiraterone exposure and reduced efficacy of abiraterone Details Abiraterone Apixaban Eliquis Increased apixaban exposure Details Abiraterone Aripiprazole Abilify Increased CYP2D6 substrate exposure and an increased risk of CYP2D6 substrate-related adverse effects Details Abiraterone Atomoxetine Atoncy Increased CYP2D6 substrate exposure and an increased risk of CYP2D6 substrate-related adverse effects Details Abiraterone Avacopan Tavneos Increased CYP3A4 substrate exposure Details Abiraterone Benzphetamine Increased amphetamine exposure and increased risk of serotonin syndrome Details Abiraterone Brexpiprazole Rexulti Increased brexpiprazole exposure Details Abiraterone Canagliflozin Invokana An increased risk of severe hypoglycemia Details Abiraterone Carbamazepine Carbatrol Reduced abiraterone exposure and reduced efficacy of abiraterone Details Abiraterone Carvedilol Coreg Increased CYP2D6 substrate exposure and an increased risk of CYP2D6 substrate-related adverse effects Details Abiraterone Cerivastatin Increased CYP2C8 substrate exposure and an increased risk of CYP2C8 substrate-related adverse effects Details Abiraterone Chlorpropamide Diabinese® An increased risk of severe hypoglycemia Details Abiraterone Cilostazol Pletal® Increased cilostazol exposure Details Abiraterone Clarithromycin Biaxin Increased exposure of CYP3A4 substrate and risk for toxicity Details Abiraterone Clomipramine Anafranil Increased CYP2D6 substrate exposure and an increased risk of CYP2D6 substrate-related adverse effects Details Abiraterone Clozapine Clozaril Increased clozapine exposure Details Abiraterone Codeine Tuzistra XR® (as a combination product containing Chlorpheniramine, Codeine) Increased codeine exposure and reduced active metabolite (morphine) exposure Details Abiraterone Conivaptan Vaprisol Increased CYP3A substrate exposure Details Abiraterone Dabigatran Etexilate Increased dabigatran etexilate exposure Details Abiraterone Dabrafenib Tafinlar Increased dabrafenib exposure Details Abiraterone Dapagliflozin Farxiga An increased risk of severe hypoglycemia Details Abiraterone Desipramine Norpramin Increased CYP2D6 substrate exposure and an increased risk of CYP2D6 substrate-related adverse effects Details Abiraterone Desloratadine Clarinex Increased CYP2C8 substrate exposure and an increased risk of CYP2C8 substrate-related adverse effects Details Abiraterone Deutetrabenazine Austedo Increased CYP2D6 substrate exposure and an increased risk of CYP2D6 substrate-related adverse effects Details Abiraterone Dextroamphetamine Dexedrine Increased amphetamine exposure and increased risk of serotonin syndrome Details Abiraterone Dihydrocodeine Increased dihydrocodeine exposure and reduced exposure of active metabolite Details Abiraterone Domperidone Increased domperidone exposure and an increased risk of QT interval prolongation Details Abiraterone Donepezil Adlarity Increased donepezil exposure Details Abiraterone Doxepin Prudoxin Increased CYP2D6 substrate exposure and an increased risk of CYP2D6 substrate-related adverse effects Details Abiraterone Doxorubicin Adriamycin Increased DOXOrubicin exposure Details Abiraterone Doxorubicin Hydrochloride Liposome Increased DOXOrubicin exposure Details Abiraterone Dulaglutide Trulicity An increased risk of severe hypoglycemia Details Abiraterone Duloxetine Increased CYP2D6 substrate exposure and an increased risk of CYP2D6 substrate-related adverse effects Details